BioSpace News Archive

Ionis scientists, including CEO Stanley Crooke, M.D., Ph.D., recognized with prestigious Paper of the Year Award for their work on advancing core antisense research

Company Completes Enrollment of Subjects in Trial Designed to Evaluate Safety and Performance of Its Three-Stent System in Standalone Procedure for Advanced Glaucoma

In pre-clinical studies Namodenoson™ significantly reduced liver inflammation and fibrosis via de-regulation of the Wnt and the NF-kB mechanistic pathway

Rheostat Therapeutics, an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons, today announced the company has changed its name to Caraway Therapeutics.

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, is pleased to announce that James Sapirstein has been appointed to serve as the Company’s President and Chief Executive Officer following the resignation of Thijs Spoor from the same positions

MediPharm Labs Corp is pleased to announce its wholly-owned subsidiary, MediPharm Labs Inc. has closed a credit agreement with a top 5 Canadian Schedule 1 bank for an aggregate $38.7 million.

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Krystal’s application for orphan designation of KB105, for the treatment of transglutaminase-1 (TGM1) deficient autosomal recessive congenital ichthyosis (ARCI)

Tabula Rasa HealthCare® (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, will deepen its clinical intelligence footprint through subsidiary company SinfoníaRx’s strategic partnership with Drake University’s College of Pharmacy & Health Sciences

Lipocine Inc. (NASDAQ: LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the H.C. Wainwright 3rd Annual NASH Investor Conference

TECLens, a medical device manufacturer, today announced the completion of enrollment of its pilot clinical study for the treatment of Keratoconus using the TECLens’ CXLens® ‘on-eye’ cross-linking system for corneal remodeling.